Shortly after having finished his degree in 1987, Kåre Schultz joined Novo Nordisk A/S in 1989. In January 2014, he was appointed Novo Nordisk A/S’s President and Chief Operating Officer (COO). Kåre Schultz joined Lundbeck in May 2015.
Kåre Schultz holds a Master of Science in Economics from the University of Copenhagen, Denmark.
Kåre Schultz is Chairman of the Board of Royal Unibrew A/S and a member of the Board of LEGO A/S, both in Denmark.
Following his degree in medicine and research fellow positions at Copenhagen hospitals, Anders Gersel Pedersen worked for Eli Lilly for 11 years: 10 of these as a director overseeing worldwide clinical research in oncology. In 2000 he joined Lundbeck as Vice President of International Clinical Research, he was later appointed Executive Vice President of Drug Development and in 2011 appointed responsible for all Research & Development activities at Lundbeck.
He is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. Anders Gersel Pedersen also serves on the Board of Directors at Bavarian Nordic A/S and ALK-Abelló A/S and is Chairman in Genmab A/S.
After finishing his education, Anders Götzsche joined PriceWaterhouseCoopers in 1991. From 1998 he was a Sales Manager with the SAS Institute until 2001, after which he became Director of Group Accounting and Reporting in Group 4 Falck. From 2005 he held the post of Chief Financial Officer for the Berlingske Officin. He joined Lundbeck in 2007.
Anders Götzsche holds a Master of Science in Accounting from University of Southern Denmark (1991) and he became a state authorized public accountant in 1997.
Anders Götzsche is the Chairman in Rosborg Møbler A/S and serves on the Board of Directors of Veloxis Pharmaceutical A/S.
Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in a number of positions including Finance, Investor Relations and Communication and has worked in Lundbeck affiliates in the US for approximately four years.
Jacob Tolstrup is head of Corporate Functions which comprises Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs.
Jacob Tolstrup holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.
Having completed his degree Lars Bang began his career at Lundbeck in 1988 as trainee in R&D. He has later been heading R&D Planning, Corporate Planning and Strategy, Lundbeck España S.A , Group Sales & Marketing. In 2003 he was appointed Group Senior Vice President Supply Operations & Engineering.
Lars Bang holds a Master of Science degree in Engineering from the Technical University of Denmark and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School.
Lars Bang is member of the Board of Fertin Pharma A/S.
Having completed his degree in Business Administration, Staffan Schüberg joined Lundbeck in 1995. In 2001 he was appointed Managing Director of Lundbeck Portugal, after which he became responsible for Southern & Western Europe, and in 2010 he was appointed President and Chairman of Lundbeck US. Staffan Schüberg has been Group Chief Commercial Officer since 1 January 2016.
Staffan Schüberg holds a BA (Hons) in Business Administration from the London Guildhall University.
Staffan Schüberg serves on the Board of Director of PhRMA (Pharmaceutical Research and Manufacturers of America).